Skip to main content
Medic Debate
- The Antidote to Medical Misinformation and Propaganda!
Languages
Dansk
Nederlands
English
Français
Deutsch
Italiano
Español
Kiswahili
Svenska
Search form
Search
Main menu
Home
Search
About us
Books
Category Search
Log In
Recent posts
Treatment Protocols
You are here
Home
Capacitabine
Items per page
5
10
20
40
60
100
Title
Average Rating
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.
50.00%
Systems biology: a therapeutic target for tumor therapy.
86.67%
Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma.
80.00%
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory.......
70.00%
Phase I trial of capecitabine (Cap) and gemcitabine (G) with concurrent radical radiotherapy in locally advanced pancreatic ca..
40.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
80.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp
60.00%
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting".
60.00%
Different metronomic treatment schedules
80.00%
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer.
40.00%
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m
80.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
40.00%
61 year old woman, Breast cancer with lymph, and lung metastasis
90.00%
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
80.00%
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu
70.00%
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
40.00%